Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Operations (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Cash from Operations data on record, last reported at 26185000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 3600.67% year-over-year to 26185000.0; the TTM value through Dec 2025 reached 5625000.0, up 94.98%, while the annual FY2025 figure was 5625000.0, 94.98% up from the prior year.
  • Cash from Operations reached 26185000.0 in Q4 2025 per ARQT's latest filing, up from 1754000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 26185000.0 in Q4 2025 and bottomed at 80344000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 39859100.0, with a median of 44551500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: plummeted 119.91% in 2021, then soared 3600.67% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 51709000.0 in 2021, then tumbled by 37.43% to 71065000.0 in 2022, then rose by 20.86% to 56244000.0 in 2023, then skyrocketed by 98.67% to 748000.0 in 2024, then skyrocketed by 3600.67% to 26185000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 26185000.0 in Q4 2025, 1754000.0 in Q3 2025, and 324000.0 in Q2 2025.